Parallel Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Parallel Advisors’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.28K	Sell	134 -57	-30%	-$481	﹤0.01%	3732
2026 Q2	$1.51K	Buy	+191	New	+$1.22K	﹤0.01%	3591
2025 Q1	–	Sell	-3,294	Closed	-$11.2K	–	3687
2024 Q4	$11.2K	Hold	3,294	–	–	﹤0.01%	2377
2024 Q3	$9.39K	Hold	3,294	–	–	﹤0.01%	2415
2024 Q2	$7.41K	Hold	3,294	–	–	﹤0.01%	2415
2024 Q1	$7.28K	Hold	3,294	–	–	﹤0.01%	2426
2023 Q4	$7.74K	Hold	3,294	–	–	﹤0.01%	2380
2023 Q3	$6.13K	Hold	3,294	–	–	﹤0.01%	2432
2023 Q2	$8.63K	Hold	3,294	–	–	﹤0.01%	2233
2023 Q1	$5.37K	Hold	3,294	–	–	﹤0.01%	2387
2022 Q4	$4.38K	Sell	3,294 -3,906	-54%	-$5.51K	﹤0.01%	2389
2022 Q3	$11K	Hold	7,200	–	–	﹤0.01%	1977
2022 Q2	$11K	Hold	7,200	–	–	﹤0.01%	1951
2022 Q1	$19K	Hold	7,200	–	–	﹤0.01%	1761
2021 Q4	$21K	Hold	7,200	–	–	﹤0.01%	1766
2021 Q3	$18K	Hold	7,200	–	–	﹤0.01%	1808
2021 Q2	$29K	Hold	7,200	–	–	﹤0.01%	1499
2021 Q1	$32K	Hold	7,200	–	–	﹤0.01%	1384
2020 Q4	$35K	Hold	7,200	–	–	﹤0.01%	1246
2020 Q3	$43K	Hold	7,200	–	–	﹤0.01%	1123
2020 Q2	$19K	Buy	+7,200	New	+$25.1K	﹤0.01%	1444

Other funds holding XERS

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Parallel Advisors's XERS Position: Q3 2026 in Review

Parallel Advisors reduced its Xeris Biopharma Holdings (XERS) stake by 30% in Q3 2026, selling an estimated $481 and leaving 134 shares worth $1.28K. The position accounts for ﹤0.01% of the portfolio, ranked #3732.

Parallel Advisors first reported a position in XERS in Q2 2020 and has held it in 21 quarters since. The position peaked at $43K in Q3 2020. 64 funds tracked by Wall St. Rank hold XERS as of Q3 2026.

Parallel Advisors held 134 shares of Xeris Biopharma Holdings worth $1.28K as of Q3 2026.
Parallel Advisors sold 57 Xeris Biopharma Holdings shares in Q3 2026, an estimated $481.
Xeris Biopharma Holdings made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3732 holding.
Parallel Advisors first reported a position in Xeris Biopharma Holdings in Q2 2020 and has held it in 21 quarters since.
Parallel Advisors's Xeris Biopharma Holdings position peaked at $43K in Q3 2020.
64 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.